Literature DB >> 24667957

The emergence of T-bodies/CAR T cells.

Zelig Eshhar1, Tova Waks, Gideon Gross.   

Abstract

The nickname "T-body" is used to denote a T cell expressing an antigen-specific or antibody-based chimeric receptor that combines antibody specificity with T-cell effector or regulatory function. Initially, we designed and constructed chimeric antibody-based receptors and expressed them in T cells to study the role of major histocompatibility complex in triggering T-cell activation. To this end, we replaced both variable domains (Vα and Vβ of the native T-cell receptor chains) with antibody-derived VH and VL sequences. After transfection into T cells, the 2 chimeric chains paired, associated with the CD3 complex, and endowed transfectants with non-major histocompatibility complex-restricted antibody type specificity. In subsequent studies, we developed next generation of chimeric antibody-based receptors by fusing an antibody single-chain variable fragment to T-cell activation motifs. This modular configuration simplified gene transfer, avoided mixed pairing with endogenous T-cell receptor chains, and enabled simultaneous insertion of various domains as costimulatory moieties to generate T-bodies with efficient antitumor reactivity.

Mesh:

Substances:

Year:  2014        PMID: 24667957     DOI: 10.1097/PPO.0000000000000027

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  19 in total

Review 1.  Adoptive T-Cell Therapy for Cancer.

Authors:  James C Yang; Steven A Rosenberg
Journal:  Adv Immunol       Date:  2016-02-03       Impact factor: 3.543

Review 2.  Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center.

Authors:  Karlo Perica; Kevin J Curran; Renier J Brentjens; Sergio A Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2018-03-01       Impact factor: 5.742

3.  The future of cellular immunotherapy for childhood leukemia.

Authors:  Challice L Bonifant; Sarah K Tasian
Journal:  Curr Opin Pediatr       Date:  2020-02       Impact factor: 2.856

Review 4.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03

5.  Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells.

Authors:  A Pato; G Eisenberg; A Machlenkin; A Margalit; G Cafri; S Frankenburg; S Merims; T Peretz; M Lotem; G Gross
Journal:  Clin Exp Immunol       Date:  2015-08-28       Impact factor: 4.330

Review 6.  Adoptive T cell immunotherapy for cancer.

Authors:  Karlo Perica; Juan Carlos Varela; Mathias Oelke; Jonathan Schneck
Journal:  Rambam Maimonides Med J       Date:  2015-01-29

Review 7.  Understanding and treating the inflammatory adverse events of cancer immunotherapy.

Authors:  Michael Dougan; Adrienne M Luoma; Stephanie K Dougan; Kai W Wucherpfennig
Journal:  Cell       Date:  2021-03-05       Impact factor: 41.582

8.  In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer.

Authors:  Béatrice Clémenceau; Sandrine Valsesia-Wittmann; Anne-Catherine Jallas; Régine Vivien; Raphaël Rousseau; Aurélien Marabelle; Christophe Caux; Henri Vié
Journal:  J Immunol Res       Date:  2015-11-17       Impact factor: 4.818

9.  An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells.

Authors:  Diana Knies; Sebastian Klobuch; Shao-An Xue; Matthias Birtel; Hakim Echchannaoui; Oezlem Yildiz; Tana Omokoko; Philippe Guillaume; Pedro Romero; Hans Stauss; Ugur Sahin; Wolfgang Herr; Matthias Theobald; Simone Thomas; Ralf-Holger Voss
Journal:  Oncotarget       Date:  2016-04-19

Review 10.  Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy.

Authors:  Vita Golubovskaya; Lijun Wu
Journal:  Cancers (Basel)       Date:  2016-03-15       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.